NCT05989711: An ongoing trial by Altimmune, Inc.
This trial is ongoing. It must report results 7 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05989711 |
|---|---|
| Title | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 27, 2023 |
| Completion date | Feb. 28, 2025 |
| Required reporting date | Feb. 28, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | July 22, 2025 |
| Days late | None |